# Paricalcitol

## Paricalcitol inj 5mcg/1mL

| TAH Drug Code      | [IPARI](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IPARI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Chronic kidney disease - Secondary hyperparathyroidism; Treatment and Prophylaxis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Dosing             | 0.04 to 0.1 mcg/kg/dose (2.8 to 7 mcg) given as an IV bolus through a hemodialysis vascular access port during dialysis; do not administer more frequently than every other day; titrate dose by 2 to 4 mcg at 2 to 4 week intervals; increase dose if intact parathyroid hormone (iPTH) level is the same， increased， or decreased by less than 30%; maintain current dose if iPTH level relative to baseline is decreased by greater than 30% to less than 60% or if the iPTH is 1.5 to 3 times the upper limit of normal; decrease dose if iPTH level is decreased greater than 60%. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Contraindications  | Hypercalcemia， Hypersensitivity to paricalcitol or any component of the product， Vitamin D toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Adverse Effects    | Common: Edema (6-7%)， Hypertension (7%)， Diarrhea (7-11%)， Nausea (6-13%)， Vomiting (5-8%)， Hypersensitivity reaction (6%)， Dizziness (5-7%)， Rhinitis (17%). Serious: Hypercalcemia (Adults， up to 6.6%; pediatric， 23%)， Gastrointestinal hemorrhage (5%)， Chronic renal failure (3%)， Angioedema.                                                                                                                                                                                                                                                                          |
| Pregnancy          | No (Limited) Human Data – Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| More Info          | [UpToDate](https://www.uptodate.com/contents/paricalcitol-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

